Goodwin Procter LLP advised HiFiBiO on the deal. HiFiBiO announced its oversubscribed $75 million Series D financing round. HiFiBiO is a multinational biotechnology company with unique expertise [...]
HiFiBiO is a Massachusetts-based biotherapeutics company that discovers, develops and commercializes antibody drugs for the treatment of cancer and autoimmune diseases.